What Companies Make GLP 1 Drugs: The Current Landscape

Introduction

The rise of metabolic health treatments has sparked a global conversation about how we approach sustainable weight loss. For many, the journey to finding an effective solution is filled with years of trial and error with restrictive diets and intense exercise routines that often lead to a cycle of frustration. Understanding which companies make GLP-1 drugs is a vital first step in navigating this rapidly evolving medical field. At TrimRx, we believe that informed patients are empowered patients, and having a clear view of the pharmaceutical landscape helps you understand the options available for your health journey. This post identifies the major manufacturers currently leading the market, those with emerging treatments in the pipeline, and the essential differences between branded and compounded options. For a broader primer on the hormone itself, what GLP-1 is can help frame the conversation.

The Pioneers: Novo Nordisk and Eli Lilly

When discussing what companies make GLP-1 drugs, two names dominate the conversation: Novo Nordisk and Eli Lilly. These pharmaceutical giants have been at the forefront of metabolic research for decades, transitioning from insulin production to the development of sophisticated hormone mimics. If you want a bigger-picture view of the treatment landscape, GLP-1 medications for weight loss is a helpful companion read.

Novo Nordisk

Novo Nordisk is a Danish pharmaceutical company that essentially brought the GLP-1 (glucagon-like peptide-1) class to the mainstream. A GLP-1 receptor agonist is a medication that mimics a naturally occurring hormone in your body that tells your brain you are full and slows down your digestion. Their most famous medications include:

• Ozempic® (semaglutide): Originally approved for the treatment of type 2 diabetes, it gained widespread attention for its secondary effect on weight management.
• Wegovy® (semaglutide): This is the same active ingredient as Ozempic® but is specifically FDA-approved for chronic weight management in adults with obesity or overweight and at least one weight-related condition.
• Saxenda® (liraglutide): An older, daily injectable medication that was the first GLP-1 approved specifically for weight loss.
• Rybelsus® (semaglutide): An oral tablet version of semaglutide, currently approved for type 2 diabetes management.

Eli Lilly

Eli Lilly, based in the United States, introduced a slightly different approach with tirzepatide. While semaglutide targets the GLP-1 receptor alone, tirzepatide is a dual-agonist. This means it targets both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor, which may offer enhanced metabolic benefits for some individuals. If you want a deeper explanation of the dual-hormone mechanism, understanding how tirzepatide works breaks it down in more detail. Their primary products are:

• Mounjaro® (tirzepatide): FDA-approved for the treatment of type 2 diabetes.
• Zepbound® (tirzepatide): FDA-approved for chronic weight management, utilizing the same dual-hormone mechanism to support weight loss.
• Trulicity® (dulaglutide): An older GLP-1 medication used primarily for blood sugar control in type 2 diabetes.

Key Takeaway: Novo Nordisk and Eli Lilly are the current market leaders, producing the most well-known branded GLP-1 medications like Wegovy® and Zepbound®.

Historical and Specialized Manufacturers

While the “Big Two” hold the majority of the market share, other established companies were early participants in the GLP-1 space or offer specialized versions of these treatments.

AstraZeneca

AstraZeneca was an early pioneer in the GLP-1 market. They produced Byetta® (exenatide), which was the first GLP-1 receptor agonist approved in the United States back in 2005. They also manufacture Bydureon®, a long-acting version of exenatide. While these are less commonly prescribed for weight loss today compared to newer medications, they laid the clinical groundwork for the current generation of treatments.

Sanofi

Sanofi is another major pharmaceutical company that entered the space with Adlyxin® (lixisenatide). This medication is typically used in combination with insulin for type 2 diabetes management. Sanofi’s focus has remained more closely aligned with diabetes care rather than broad-scale weight management indications.

The Future: Emerging Companies in the GLP-1 Space

The success of semaglutide and tirzepatide has led to a “gold rush” in the pharmaceutical industry. Several major companies and smaller biotech firms are currently in the clinical trial phases of developing new GLP-1 or multi-hormone agonists.

Pfizer

Pfizer is actively working to enter the market with an oral GLP-1 medication. While they have faced some setbacks in clinical trials, they are currently advancing danuglipron, a once-daily pill. The goal of companies like Pfizer is to create a “small molecule” drug that is easier to manufacture and more convenient for patients who prefer a pill over an injection.

Amgen

Amgen is developing a drug currently known as MariTide. This medication is unique because it targets the GLP-1 receptor but actually blocks the GIP receptor (unlike Eli Lilly’s drug, which activates it). Early research suggests that this approach might allow for less frequent dosing—potentially once a month rather than once a week—which could significantly improve the patient experience.

Viking Therapeutics

Viking Therapeutics is a smaller biotech company that has gained significant attention for its candidate, VK2735. This is another dual GLP-1 and GIP receptor agonist. Their early trial data has shown promising results in weight reduction, and they are exploring both injectable and oral formats.

Roche and Zealand Pharma

Swiss giant Roche recently entered the space by acquiring Carmot Therapeutics, gaining access to several promising GLP-1/GIP candidates. Meanwhile, Zealand Pharma is collaborating with Boehringer Ingelheim on survodutide, a medication that targets GLP-1 and glucagon, which helps with energy expenditure and liver health.

Note: Many of the medications from companies like Pfizer, Amgen, and Viking Therapeutics are still in clinical trials and are not yet available for public use. Always consult with a healthcare provider about currently available treatment options.

Branded vs. Compounded GLP-1 Medications

When researching what companies make GLP-1 drugs, you will likely encounter the distinction between branded medications and compounded versions. This is a critical area for patients to understand, as it relates to how the medication is made and how it is accessed.

Branded Medications

Branded drugs like Wegovy® or Zepbound® are manufactured by the original patent holders (Novo Nordisk and Eli Lilly). These medications have undergone the full FDA approval process as finished drug products. They are manufactured in large-scale facilities and distributed in specific, pre-filled injector pens. Because of high demand and complex manufacturing, these branded products frequently face supply shortages.

Compounded Medications

Compounded Semaglutide and Compounded Tirzepatide are different. These are not “generic” versions, as the patents for these drugs have not yet expired. Instead, they are prepared by licensed pharmacists in FDA-registered and inspected compounding pharmacies. If you want a deeper look at the mechanics, how compounded semaglutide works for weight loss is a useful companion read.

Myth: Compounded GLP-1 medications are “fake” or “illegal.” Fact: When a drug is listed on the FDA’s drug shortage list, licensed compounding pharmacies are legally permitted under federal law to prepare versions of those medications to help meet patient needs.

It is vital to understand that Compounded Semaglutide and Compounded Tirzepatide are not FDA-approved in the way branded drugs are. While the pharmacies themselves are regulated and the ingredients are sourced from high-quality suppliers, the specific compounded mixture has not gone through the same clinical trials as the branded pen. Many patients choose this route because it offers a more consistent supply during shortages and can be more easily tailored to specific dosages.

How the TrimRx Platform Connects You to Care

Understanding the long list of manufacturers can be overwhelming. At TrimRx, we simplify this process by acting as a bridge between you and the clinical expertise needed to start your journey. If you’re ready to see whether a personalized program is a fit, take the free assessment quiz.

Through our platform, you can access a personalized program that includes:

• Medical Consultation: You are connected with a licensed healthcare provider who reviews your medical history, health goals, and lab work to determine if a GLP-1 medication is right for you.
• Pharmacy Coordination: We work with FDA-registered and inspected compounding pharmacies to ensure that your medication is prepared and shipped directly to your door.
• Continuous Support: Our program includes unlimited support from our team of specialists, ensuring you have a guide through every step of the process.

We focus on a transparent model that keeps your care simple. Whether your provider adjusts your dosage or keeps it steady, the program remains consistent. This approach ensures that your focus remains on your health and lifestyle changes rather than navigating the complexities of pharmaceutical supply chains.

The Mechanism: How These Companies Design Their Drugs

Every company mentioned above is trying to solve the same problem: how to regulate the body’s metabolic signals to support sustainable weight loss. The reason there are so many different companies involved is that the human body has several different hormone pathways that control hunger and energy.

Single Agonists vs. Dual Agonists

Most of the original research focused on GLP-1 alone. Medications like semaglutide (Wegovy®) mimic the GLP-1 hormone, which primarily works by:

1. Stimulating Insulin: Helping the pancreas release the right amount of insulin when blood sugar is high.
2. Slowing Gastric Emptying: Keeping food in your stomach longer so you feel full for a greater duration.
3. Brain Signaling: Acting on the hypothalamus to reduce cravings and appetite.

Newer companies are looking at “multi-agonists.” By combining GLP-1 with GIP or Glucagon, they hope to tackle obesity from multiple angles—such as increasing the calories your body burns while simultaneously decreasing the calories you consume.

The Importance of Professional Guidance

Regardless of which company manufactures the medication, GLP-1 treatments are powerful medical tools. They are not “quick fixes” and require a commitment to lifestyle changes, including nutrition and physical activity. If you want a framework for building habits that last, how to start a weight loss journey that actually lasts is a worthwhile read. Because these medications can have side effects—most commonly gastrointestinal issues like nausea or constipation—it is essential to be under the care of a professional.

A personalized program allows for careful monitoring of your progress. A provider can help you manage side effects, ensure you are maintaining lean muscle mass, and help you decide if a particular medication is the best fit for your unique biology.

Bottom Line: The GLP-1 market is currently dominated by Novo Nordisk and Eli Lilly, but many other companies like Amgen and Pfizer are developing the next generation of treatments. Accessing these medications through a supervised program is the safest and most effective way to reach your goals.

The Role of Supplements in GLP-1 Therapy

For those who are either on a prescription program or looking for natural ways to support their metabolic health, some companies offer supplemental support. At TrimRx, we offer quick-access supplements like GLP-1 Daily Support. These are designed to complement a healthy lifestyle by supporting the body’s natural pathways. These supplements do not require a medical quiz and can be purchased directly to support your overall wellness journey.

Another option is Weight Loss Boost, which is designed to complement a healthy lifestyle.

If you want to explore the category first, what a natural GLP-1 supplement can do for your weight loss journey offers helpful context.

Summary of the Manufacturing Landscape

The world of GLP-1 medications is growing every day. Here is a quick summary of where things stand:

• Market Leaders: Novo Nordisk (Wegovy®) and Eli Lilly (Zepbound®).
• Historical Players: AstraZeneca and Sanofi.
• The Future Pipeline: Pfizer, Amgen, Viking Therapeutics, and Roche.
• Access Alternatives: FDA-registered compounding pharmacies providing personalized versions of semaglutide and tirzepatide.

The best choice for your health depends on your medical history, your insurance coverage, and your personal preferences regarding injections or oral medications. By working with a platform that prioritizes your individual needs, you can navigate these choices with confidence.

Conclusion

The pharmaceutical landscape for weight loss has changed forever. Knowing what companies make GLP-1 drugs helps you see beyond the brand names and understand the science driving your treatment. While Novo Nordisk and Eli Lilly currently lead the way, the entrance of new innovators ensures that the field will continue to improve, offering more convenience and better results for patients. For readers thinking beyond the first prescription, maintaining weight loss after tirzepatide is a useful next read.

TrimRx is committed to being your partner in this journey, merging clinical expertise with the ease of modern technology. We believe in a future where weight management is personalized, empathetic, and science-backed. Whether you are just starting to research your options or are ready to take the next step, our mission is to support you in achieving sustainable, healthy weight loss.

Your Next Step: Are you ready to see if a personalized weight loss program is right for you? Take our free assessment quiz to get started and discover the treatment plan that fits your life.

FAQ

Which company makes the weight loss drug Wegovy®?

Wegovy® is manufactured by Novo Nordisk, a Danish pharmaceutical company that specialized in diabetes care for decades before becoming a leader in obesity treatment. It contains the active ingredient semaglutide, which is the same ingredient found in their diabetes medication, Ozempic®.

Does Pfizer have a GLP-1 drug for weight loss?

Pfizer is currently in the process of developing an oral GLP-1 medication known as danuglipron. While it is not yet available for public use, it is being studied in clinical trials as a potential pill-based alternative to the current injectable treatments on the market.

What is the difference between branded and compounded GLP-1 drugs?

Branded GLP-1 drugs are the specific, finished products made by patent holders like Novo Nordisk or Eli Lilly and are FDA-approved as a whole. Compounded GLP-1 drugs are prepared by licensed pharmacists in FDA-registered pharmacies and are often used during branded drug shortages, though the specific compounded mixture is not itself FDA-approved.

Are there any companies making oral GLP-1 medications?

Yes, Novo Nordisk currently makes an oral semaglutide called Rybelsus®, which is approved for type 2 diabetes. Several other companies, including Pfizer and Viking Therapeutics, are currently testing oral versions specifically for weight loss in various stages of clinical trials. If you’re comparing options, take the free assessment quiz to see whether a personalized program fits your goals.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.